浙江海翔药业股份有限公司投资者关系活动记录表 证券代码：002099 证券简称：海翔药业 编号：2025-003 | | 货，配合客户开展全球市场注册变更；同时另有原产厂合作 | | | | --- | --- | --- | --- | | | 的抗感染产品完成验证批发货，将开展验证工作。多肽平台 | | | | | 产品已成功切入原研药企配套产业链，本年度在不断扩大现 | | | | | 有合作产品的供应量的同时，积极拓展高附加值新项目合 | | | | | 作，扩展多肽平台收入规模和发展空间。 | | | | | 3、公司对于制剂业务如何规划？ | | | | | 答：目前公司已有 3 个制剂产品通过一致性评价，1 个 | | | | | 产品中标国家集采，业务体量偏小，暂不考虑自建销售团队， | | | | | 主要采取参加集采和其他销售企业合作方式拓展市场销售。 | | | | | 现有3个制剂在CDE评审中，未来也将持续拓展制剂新品种， | | | | | 丰富制剂板块产品线，打造"中间体-原料药-制剂"一体化 | | | | | 产业平台。同时公司积极与海外制剂企业开展合作，探索制 | | | ...

证券代码：300683 证券简称：海特生物 尊敬的投资者，您好！已有相关临床前研究表明，注射用埃 普奈明可能通过影响免疫微环境的方式，对接受 CAR-T 细胞回输 的患者体内的 CAR-T 细胞扩增产生积极影响，且由于注射用埃普 奈明起效迅速、安全性良好等特点，正在越来越多的进入到国内 主流的血液病医院的 CAR-T 治疗过程中，而包括中国医学科学院 血液病医院、西部战区总医院在内的国内一线血液病医院也在积 极与我司合作开展埃普奈明用于CAR-T前桥接化疗及CAR-T后的 维持治疗等方向的临床试验研究。谢谢 4、研发管线最新的收获进展情况是怎样的？ 尊敬的投资者，您好！公司的在研产品及进展已在定期报告 中披露，请关注公司的定期报告。谢谢。 5、请问埃普奈明新产线布局在哪里？已经立项和开建了 吗？ 尊敬的投资者，您好！埃普奈明新产线布局在武汉海特生物 制药股份有限公司园区内，新扩建的产线正在建设过程中。谢谢。 6、杨总，北京沙东的剩下的股权有没有考虑收购，是不是 埃普奈明销售不及预期，可能不考虑剩下的股权收购了。 尊敬的投资者，您好！埃普奈明销售顺利，符合公司预期， 公司会按照股权收购协议的约定履行相应的义务， ...

Investment Rating - The report maintains a "Buy" rating for the company [1]. Core Views - The company reported better-than-expected performance in Q4 2024, with a focus on optimizing the supply chain for its plant protection business [5][6]. - The company's revenue for 2024 was 5.68 billion yuan, a decrease of 11.88% year-on-year, but it achieved a net profit of 103 million yuan, marking a return to profitability [5][6]. - The plant protection business experienced a revenue decline due to falling pesticide prices, but gross margins improved due to technological innovation and management optimization [6][7]. - The company is expanding its supply chain layout with a new production base in Malaysia, enhancing its service offerings across the product lifecycle [7]. Summary by Sections Financial Performance - In Q4 2024, the company achieved a revenue of 1.32 billion yuan, down 7.44% year-on-year, but net profit reached 70.64 million yuan, a significant increase of 285% quarter-on-quarter [5]. - For Q1 2025, revenue was 1.51 billion yuan, up 3.02% year-on-year and 14.55% quarter-on-quarter, with a net profit of 49.72 million yuan, reflecting a year-on-year growth of 1747% [5]. Business Segments - The pharmaceutical segment generated 1.29 billion yuan in revenue, down 13.3% year-on-year, but gross margin improved by 13.1 percentage points to 48.0% [6]. - The plant protection segment had a revenue of 3.59 billion yuan, down 15.4% year-on-year, with a gross margin increase of 5.8 percentage points to 20.1% [6]. Future Outlook - The company has revised its profit forecasts for 2025-2027, expecting net profits of 305 million yuan, 415 million yuan, and 536 million yuan respectively, reflecting a positive outlook based on industry recovery and improved margins [8][9]. - The report highlights the company's ongoing projects in the pharmaceutical sector, including six validation projects, with a focus on API and innovative drug intermediates [7][8].